Skip to main content

AnaptysBio, Inc.

corporate_fare Company Profile

AnaptysBio, Inc.

ANAB·NASDAQ·Life Sciences·CIK 0001370053

ANAPTYSBIO, INC is a clinical-stage biotechnology company that develops immunology therapeutics for autoimmune and inflammatory diseases. The company's clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, which completed a Phase 2b trial for moderate-to-severe rheumatoid arthritis (RA). ANB033, a CD122 antagonist, is in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE). ANB101, a BDCA2 modulator, is in a Phase 1a trial. ANAPTYSBIO, INC also discovered and out-licensed multiple therapeutic antibodies through financial collaborations. These include a PD-1 antagonist, Jemperli (dostarlimab-gxly), licensed to GSK, and an IL-36R antagonist, imsidolimab, licensed to Vanda Pharmaceuticals Inc. The company currently generates revenue from milestones and royalties under its immuno-oncology collaboration with GSK and from license and transition services revenue from its collaboration with Vanda. In September 2025, the company announced plans to explore separating its business into two independent, publicly traded companies. One company is expected to manage the financial collaborations for Jemperli from GSK and imsidolimab from Vanda, focusing on protecting and returning royalty value to shareholders. The other company is expected to be a clinical-stage biotechnology company focused on developing and potentially commercializing innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. This proposed separation is expected to be completed in the second quarter of 2026.

AnaptysBio, Inc. (NASDAQ:ANAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 46 items for ANAB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 11 rated 8 or above. Recent SEC coverage for ANAB spans SCHEDULE 13D/A, 4, 10-Q, 10-KT.

Recent high-impact activity:

  • EcoR1's Nodelman Lifts AnaptysBio Stake to 27.8% After $17.2M Buying Run
  • EcoR1's Oleg Nodelman Buys $17.2M of AnaptysBio Stock in Three-Day Open-Market Run
  • AnaptysBio 10-Q: $3.9M Q3 Income, $153M Cash, GSK Royalty Case Awaits Ruling
  • AnaptysBio Swings to $3.9M Q3 Profit on $30.3M Collaboration Revenue
  • AnaptysBio Slides 8% as Delaware Hearing Opens in GSK/Tesaro Contract Fight

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$234.6M
Net Income
-$13.23M
Diluted EPS
-$0.46
Op. Cash Flow
$19.7M
Free Cash Flow
$19.61M
Operating Income
$47.9M
Cash & Equivalents
$238.2M
Debt / Equity
0.00×
Net Margin
-5.6%
Shares Outstanding
28.02M sh
Source: 10-K · filed 2026-04-28 · accession 0001193125-26-187044

Short Interest & Short Volume

10.79 days to cover

FINRA reported short interest of 5,050,250 shares in ANAB as of the October 30, 2026 settlement, a 6.3% decrease from the prior period — about 10.8 days to cover at its recent average daily volume. On November 20, 2026, 54.1% of ANAB volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)5,050,250 shares as of October 30, 2026
Change vs prior period▼ 6.3%
Days to cover10.79 at avg daily volume of 468,120
Daily short volume (FINRA facilities)54.1% of 146,167 shares on November 20, 2026
5-day average short volume48.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$46.63
52-week range · as of 2026-11-19 $22.06 – $72.36
Market cap
$1.39B
Volume
432.4K (1.0× avg)
3-mo avg 429.8K
Live data · 2026-11-22 07:59 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ANAB - Latest Insights

ANAB
Nov 18, 2026, 7:03 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $47.74
Real-time Price: $46.63 info
Change: -$1.11 (-2%) info
Market Cap: $1.386B info
ANAB
Nov 18, 2026, 6:56 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $47.06
Real-time Price: $46.63 info
Change: -$0.430 (-0.91%) info
Market Cap: $1.386B info
ANAB
Nov 12, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $46.63 info
Change: -$1.14 (-2%) info
Market Cap: $1.386B info
ANAB
Nov 12, 2026, 4:16 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $46.63 info
Change: -$1.14 (-2%) info
Market Cap: $1.386B info
ANAB
Oct 20, 2026, 3:49 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $45.00
Real-time Price: $46.63 info
Change: +$1.63 (+4%) info
Market Cap: $1.386B info
ANAB
Oct 19, 2026, 2:18 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $49.23
Real-time Price: $46.63 info
Change: -$2.60 (-5%) info
Market Cap: $1.386B info
ANAB
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $50.85
Real-time Price: $46.63 info
Change: -$4.22 (-8%) info
Market Cap: $1.386B info
ANAB
Sep 21, 2026, 4:23 PM EDT
Filing Type: 10-KT
Importance Score:
8
Price at Filing: $55.99
Real-time Price: $46.63 info
Change: -$9.36 (-17%) info
Market Cap: $1.386B info
ANAB
Sep 21, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $55.99
Real-time Price: $46.63 info
Change: -$9.36 (-17%) info
Market Cap: $1.386B info
ANAB
Sep 21, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $55.99
Real-time Price: $46.63 info
Change: -$9.36 (-17%) info
Market Cap: $1.386B info
ANAB
Jun 29, 2026, 4:15 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $65.97
Real-time Price: $46.63 info
Change: -$19.34 (-29%) info
Market Cap: $1.386B info
ANAB
Jun 26, 2026, 4:46 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $63.15
Real-time Price: $46.63 info
Change: -$16.52 (-26%) info
Market Cap: $1.386B info
ANAB
Jun 22, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $59.32
Real-time Price: $46.63 info
Change: -$12.69 (-21%) info
Market Cap: $1.386B info
ANAB
Jun 17, 2026, 4:29 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $56.77
Real-time Price: $46.63 info
Change: -$10.14 (-18%) info
Market Cap: $1.386B info
ANAB
Jun 16, 2026, 5:28 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $57.60
Real-time Price: $46.63 info
Change: -$10.97 (-19%) info
Market Cap: $1.386B info
ANAB
Jun 15, 2026, 5:47 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $56.47
Real-time Price: $46.63 info
Change: -$9.84 (-17%) info
Market Cap: $1.386B info
ANAB
Jun 12, 2026, 4:07 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $56.07
Real-time Price: $46.63 info
Change: -$9.44 (-17%) info
Market Cap: $1.386B info
ANAB
Jun 11, 2026, 4:47 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $54.24
Real-time Price: $46.63 info
Change: -$7.61 (-14%) info
Market Cap: $1.386B info
ANAB
Jun 10, 2026, 4:38 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $52.10
Real-time Price: $46.63 info
Change: -$5.47 (-10%) info
Market Cap: $1.386B info
ANAB
Jun 09, 2026, 5:08 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $51.63
Real-time Price: $46.63 info
Change: -$5.00 (-10%) info
Market Cap: $1.386B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets